A study on the value of folic acid combined with helicobacter pylori eradication therapy in treating chronic atrophic gastritis
叶酸联合幽门螺杆菌根除治疗慢性萎缩性胃炎的价值研究

摘要

目的 探讨研究叶酸联合幽门螺杆菌根除治疗慢性萎缩性胃炎的价值。方法 选取本医院2024年6月-2025年6月收治的200例慢性萎缩性胃炎患者为研究对象，随机分为单一组和联合组，每组100例。单一组给予常规幽门螺杆菌根除治疗，联合组在单一组基础上联合叶酸治疗，并对比两组Hp根除率、临床症状改善、胃黏膜病理病变以及不良反应发生率。结果 联合组的Hp根除率显著提高，临床症状和胃黏膜病理病变改善更显著，均优于单一组，差异具有统计学意义（p<0.05）；两组不良反应发生率比较，无显著差异（p<0.05）。结论 叶酸联合幽门螺杆菌根除治疗可以显著提高慢性萎缩性胃炎患者的Hp根除率，改善临床症状及胃黏膜癌前病变，且安全性良好，具有临床推广和应用价值。

Abstract

Objective To investigate the value of folic acid combined with Helicobacter pylori (Hp) eradication therapy in treating chronic atrophic gastritis.
Methods 200 patients with chronic atrophic gastritis admitted to our hospital from June 2024 to June 2025 were selected as study subjects and randomly divided into a monotherapy group and a combination group, with 100 cases in each group. The monotherapy group received conventional Hp eradication therapy, while the combination group received folic acid in addition to the conventional therapy. The Hp eradication rate, improvement in clinical symptoms and gastric mucosal pathological lesions, and the incidence of adverse reactions were compared between the two groups.
Results The combination group showed a significantly higher Hp eradication rate. Improvements in clinical symptoms and gastric mucosal pathological lesions were more significant in the combination group compared to the monotherapy group, and the differences were statistically significant (p < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (p > 0.05).
Conclusion   Folic acid combined with Hp eradication therapy can significantly increase the Hp eradication rate in patients with chronic atrophic gastritis, improve clinical symptoms and gastric mucosal precancerous lesions, and is safe. It holds value for clinical promotion and application.